Live search
TopFind is fetching the latest matches for your search.
We reviewed 10000 live results for besremi clinical consultation and administration and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Healthcare Service and Haematology Clinic.
Source: Centre for Clinical Haematology (CFCH)
Description
Professional medical service involving the specialist consultation, prescription, and clinical administration of Besremi (ropeginterferon alfa-2b) for the treatment of Polycythemia Vera. The service includes patient monitoring and expert management of Myeloproliferative Neoplasms (MPNs) in a clinical setting.
Best for
MPN patient management, supervised biological injections, specialist haematology advice and private oncology care
Rating
Source: PharmaEssentia Singapore Pte. Ltd.
Description
Besremi is a prescription-only biological therapeutic specifically approved for the treatment of Polycythemia Vera (PV) in adults. This long-acting monopegylated interferon is delivered as a 500 micrograms/mL solution for injection in a prefilled syringe, designed for convenient administration and prolonged therapeutic effect in managing myeloproliferative neoplasms (MPN). It was officially launched in Singapore in September 2024 following approval by the Health Sciences Authority (HSA).
Best for
patients with Polycythemia Vera, long-acting interferon therapy, specialized haematology care and prescription biological treatments
Rating
Source: PharmaEssentia
Description
Besremi (ropeginterferon alfa-2b) is a solution for injection provided in a 500 mcg/mL pre-filled syringe. It is a monopegylated interferon specifically indicated for the treatment of adults with Polycythemia Vera (PV). It was recently registered by the Health Sciences Authority (HSA) in May 2024 and launched in Singapore in September 2024 as a new long-acting interferon option.
Best for
Polycythemia Vera patients, long-acting interferon therapy, newly registered HSA treatments and hematology patients
Rating
| Compare | Besremi Clinical Consultation and Administration | Besremi (ropeginterferon alfa-2b) | Besremi |
|---|---|---|---|
| Source | Centre for Clinical Haematology (CFCH) | PharmaEssentia Singapore Pte. Ltd. | PharmaEssentia |
| Description | Professional medical service involving the specialist consultation, prescription, and clinical administration of Besremi (ropeginterferon alfa-2b) for the treatment of Polycythemia Vera. The service includes patient monitoring and expert management of Myeloproliferative Neoplasms (MPNs) in a clinical setting. | Besremi is a prescription-only biological therapeutic specifically approved for the treatment of Polycythemia Vera (PV) in adults. This long-acting monopegylated interferon is delivered as a 500 micrograms/mL solution for injection in a prefilled syringe, designed for convenient administration and prolonged therapeutic effect in managing myeloproliferative neoplasms (MPN). It was officially launched in Singapore in September 2024 following approval by the Health Sciences Authority (HSA). | Besremi (ropeginterferon alfa-2b) is a solution for injection provided in a 500 mcg/mL pre-filled syringe. It is a monopegylated interferon specifically indicated for the treatment of adults with Polycythemia Vera (PV). It was recently registered by the Health Sciences Authority (HSA) in May 2024 and launched in Singapore in September 2024 as a new long-acting interferon option. |
| Best for | MPN patient management, supervised biological injections, specialist haematology advice and private oncology care | patients with Polycythemia Vera, long-acting interferon therapy, specialized haematology care and prescription biological treatments | Polycythemia Vera patients, long-acting interferon therapy, newly registered HSA treatments and hematology patients |
| Tags | |||
| Action | View Details | View Details | View Details |
| Rating |
If you want the most balanced option to start with, I recommend:
"Besremi Clinical Consultation and Administration from Centre for Clinical Haematology (CFCH)."
I picked this because As a key clinical site involved in the therapy's launch, this clinic offers specialized medical expertise and a supervised environment for patients beginning Besremi treatment.